…and the Winner is: The Individualized Therapy!*

Adjuvant chemotherapy is indicated in most breast cancer patients with intermediate and high risk (table 1). There are many chemotherapy regimens available and unfortunately most have not been compared to each other in prospective, randomized trials. Since different members of the St. Gallen panel carried out trials of various chemotherapies, they were advocating ‘their’ regimen and the discussion resulted in proposing several treatments that appeared to lead to similar results.